Ackenheil, M. 613 Alps, B. J. 569 Aman, M. G. 621 Aulakh, C. S. 129

Baez, L. A. 123,269 Ban, T. A. 561 Barkley, P. 269 Beregi, L. 34 I Best, J. 75 Bhattacharyya, A. K. 129 Blurtdell, J. E. 319 Bonicalzi. M. 607 Bonilla. E. 277 Bouyard, P. 247 Browning, R. A. 123 Bruguerolle, B. 247 Bunting, P. R. 327 Burger, A. B. 153 Burgess, C. D. 523

Campbell, 1. C. 303 Caplan, R. 215 Caponeri, M. A. 607 Carroll, B. J. 101 Chermat, R. 241 Choi, S. J. 107 Chneschmidt, B. V. 327 Cox, J. 75 Cox, J. R. 293 Cusatis, M. 123

D’auteuil. C. 91 Deanovic, Z. 253 Debus, G. 39 I De Maio, D. 607 De Met, E. M. 43 Denber, H. C. B. 51 Deniker, P. 455 Dennis. S. G. I I I Denver; D. 313 Derman, R. M. 107 Desarmenien, M. 31 Diez-Ewald, M. 277 Downing, R. W. 405 Dubois, J. P. 293 Dufour, M. 9 I Duhault, J. 341

AUTHOR INDEX

Eckbert, B. 57 Elizur, A. 21 I Evans, L. 75 Evans, L. E. J. 293

Feldmann, H. S. 51 Feltz, P. 3 I Fiedorowicz, C. 207 Fink, M. 495 Fischer-Cornelssen, K. A. 545 Flint, B. A. 233 Frances. H. 241

Garattini, S. 317,363 Garcin, F. 313 Garside. R. F. 303 Gaudreault, V. 313 Gebhart, G. F. 153 Gelbart, J. 101 Ghoneim, M. M. 81 Ghosh, 8. 129 Giurgea, C. 443 Glares, A. G. 601 Golinko, B. E. 601 Gonzalex, J. V. 277 Gottfries. C. G. 57, 185 Greil, W. 199 Grtinberger. J. 417,469

Halaris. A. E. 43 Hartley, L. 193 Heffner, T. G. 351 Heimann. H. 379 Hirsch, S. R. 633 Ho, 1. K. 233 Hrdina, P. D. 591

Ichikawa, K. 17 I Itoh, H. 171 Iwamura, K. 171

Jadot, G. 247 Jamnicky, B. 253 Janke, W. 391

vii

. . . VIII

Katz, R. J. 37, 101,219,309, 585 Kawazu, Y. 285 Kenny, M. 161 Klein, W. 527 Klemm, W. R. I, 137,261 Kline, N. S. 491,519 Kopera, H. 527 Krebbs, E. 507 Kulik, F. A. 627

Lamour, Y. 3 1 Lapierre, Y. D. 59 I Latham, C. J. 319 Leonard, B. E. I61 Liberson, 2. 211 Libiger, J. 561 Lowery, S. P. 269 Lykouras, E. 69

Mallari, C. Cl. I Manchanda, R. 633 Mandel, P. 19,247 Marshall, E. F. 303 Marwaha, J. I45 Meier, K. D. 613 Mellado, C. 607 Mennini, T. 363 Mesdjian, E. 247 Mikeska, J. A. 137 Minzi, A. L. 607 Montgomery, D. B. 523 Montgomery, S. A. 523 Moore, G. 75 Morris, M. D. I53 Mountjoy, C. Q. 303 Muck-Seler, D. 253

Naber, D. 199 Nakano, S. 285 Netter, P. 375 Nick Bett, J. H. 293 Noble. E. P. I9

Ogawa, N. 285 Ohtsuka, N. I71 Oreland, L. 57, I85

Petersen, R. C. 81 Pichot. P. 435 Poeldinger, W. 507 Pradhan, S. N. 129 Pull, C. B. 435

Author Index

Pull, M. C. 435

Radouco-Thomas, C. 313 Radouco-Thomas, S. 3 I3 Rennick, 0. M. 601 Resnick, M. 207 Rickels, K. 405 Rinieris, P. 69 Rogers, P. J. 3 19 Roman, F. 341 Roszkowski, A. P. 569 Roth, M. 303 Rotman. A. 215 Roubicek, J. 507,519

Saletu, B. 417,469 Samanin, R. 363 Schenk, H. 527 Schmaltz, K. 585 Sesso, M. 607 Shepherd, M. 447 Sherry, C. J. 137,261 Silverstone, T. 371 Simeon, J.. 207,519 Simon, P. 13,241,503 Singh, P. 91 Spreux-Varoquaux, 0. I3 Stefanis, C. N. 69 Stefanovic, V. I9 Steinbock, H. 199 Stricker, E. M. 351 Syapin, P. J. I9 Szekely, Cl. A. 215

Teelken, A. W. 613 Tombros, E. 3 I9 Treffers. R. C. I45 Trites. R. 207

Valli, M. 247 Van Hees, T. 293 Varsou, E. 69 von Frenckell, R. 435 von Knorring, L. 57, I85

Wadsworth, J. 523 Wakeman. P. 621 Wallach, M. B. 569 Waterbury, L. D. 569 Waters, B. 207 Weller, M. P. I. 633 Wilbur, R. 627 Wheatley, D. 521,537 Wiberg, A. 57

Winblad, B. 57

Yagi, G. 171

Author Index

Zander, K. J. 613 Zigmond, M. J. 351 Zimmer, R. 613

ix

SUBJECT INDEX

Adverse drug reactions amitriptyline 56 chlordiazepoxide 407 chlorimipramine 295,300 clonidine 211,212 etirazetam 483 fluotracen 56 neuroleptics 627-3 I piracetam 207-9

Affective psychoses and platelet monoamine oxidase 185-90

AHR-I I I8 clinical response 46 and norepinephrine metabolism 43-8 and plasma 3-methoxy-4-hydroxyphenylglycol 45,

46 structure 43

Alcohol and dementia 562 eco-pharmacogenetic model 3 13-l 5

Amantadine and maze behaviour in mice 588 y-Aminobutyric acid (GABA)

and apomorphine treatment 166 cerebrospinal fluid levels and psychotropic drugs

613-19 in depression 617,618 normal 616 in schizophrenia 617,618

-evoked stimulation. diazepam effects 31-5 membrane potentials 32 response decay, diazepam effects 34

Amitriptyline cardiovascular effects 523-6 comparativestudy 51-5 dosage and ratings 6 IO. 6 I I heart effects 527-34 side effects 56 structure 52

AMP, cyclic and chlorpromazine in schizophrenia 72 diazepam induced 95 drug effects 96.97 neurotransmitter effects 92 psychotropicdrug effects 91-8 in schizophrenia 69-73

Amphetamine ethanol interaction in rodents 13-17 -like anorectic agents 337

d-Amphetamine behavioural effects 352 and feeding 353-5,359,360

and motor activity 355, 356 d-Amphetamine sulphate tolerance in hyperactivity

601-6 I-Amphetamine and feeding 353 Amygdala

electrode stimulation 3,4 morphine effect on evoked stimulation 8,9

Animal model in attention 585-9 Anorexia

caused by brain receptor stimulation 363-8 drug activities in rats 343 drug-induced, drug effects 327-37 drug structures 342 5-HT dependent 364-6 psychopharmacology of drugs 371-3 substituted phenylethylamines 341-8

Antidepressant drugs 419-21,461.503-5,524-6. 569-82

daily dose effects, evaluation 524, 525 doses and rating 610.61 I schedules 607, 608

Anxiety assessment 539,543 assessment methods 287,392. 393,412 and depression assessment 386-8 and psycholeptic drugs 399,400 psychophysiological reactivity 382-6 rating and chlorazepate 542 tranquillizer effect measurement 391-402 treatment in coronary heart disease 537-44

Apomorphine behaviour effects and rat strain 161-8 and maze response in mice 588

Attention, dopaminergic model 585-9 Autism, dopamine uptake 216,217

Behaviour anxiety 394,395 apomorphine and rat strain 161-8 assessment I30 dopaminergic levels 351-60 exploratory and lithium 3740 feeding 319-26.351 and methylphenidate 129-34 open field 163,272 rhythm 37-40 spiroperidol 272

Behaviour tests 14. 130 floor cooling 310

Subject Index xi

oxtremorine screening in mice 241-5 tail pinch 3 10

Blocking agents, P-adrenergic 630 Brain, functional units 445 Byte processing and ethanol 261-6

Calcium antagonism .ree D-600 Cardiovascular system

assessments 530 drug effects in depression 523-6 psychotropic drugs 527-34 RS-51324 effects 576-S

Catalepsy test and spiroperidol 270 stress-induced facilitation 309-I 1

Catecholaminergic system antagonists and feeding 352 inhibition in anorexia 332-6 neurotoxin 334.335

Cells C6 glioma 21-3 neural and ethanol 26,27

Central grey morphine and evoked excitation 8 response to substantia nigra stimulation and

morphine 6,7 Cerebroside sulphate 1 I I-20

opiate binding 112. I13 structure I12

Chlorazepate and anxiety ratings 542 blood pressure 541 and glyceryl trinitrate need in anxiety 540

Chlordiazepoxide in anxiety 396 and conditioned fear 153-8 demographic factors 406 global improvement attributes 410,411 illness history 407 improvement assessment 409 responders and non-responders 405-14 symptoms 408

Chlorimipramine bioavailability 299 oral, parenteral bioavailability 293-30 1 pharmacokinetics 296-8

p-chlorophenylalanine attack response 227 muricidal behaviour 224 predation 22 1 predation in cat 226

Chlorpromazine AMP, cyclic in mice 91-8 AMP, cyclic in schizophrenia 72 structure 52

Choice reaction time test and neuroticism 289 Cholinesterase, lithium effects 107. 108 Classification

antidepressants 460.461.503-5

biological principles 447-9 clinical categories 449-52 computer use 465-7 difficulties with new compounds 462 drugs in paediatrics 5 19 EEG use 463,464,495-500 endorphins/enkephalins 507-17 neuroleptics 459 patients and drugs; therapeutic response 491-4 pharmacoclinical of psychotropic drugs 455-67 types for drugs 492

Clinical global depression scale and antidepressants 54

Clobazam behaviour tests 289,290 structural formula 286

Clonidine. psychotic episode 21 I, 212 Cognitive-perceptive-motor battery subtests 603

repeatable 604 Continuous performance test 621-6

applicability 624-6 oscillations 622,623 playback 623 relay driver 624 system 622-5

Coronary heart disease angina attacks and treatment 540 anxiety treatment 537-44

Cycloid psychoses, monoamine oxidase 57-66 Cyproheptadine and oxtremorine symptoms 244

D-600. calcium antagonist 145-51 and action potentials 147 contractures induced I50 membrane properties 148 muscle properties 145-51 twitch tension 149, 150

DeBonis self rating scale in depression 385 Dementia

aged 565 cholinergic dysfunction 564 definitions 561 drugs-induced 561-4 experimental induction 564,565 metals and 563 protein synthesis 564,565

Depolarization, GABA evoked and diazepam 31-S Depression syndromes

assessment and state relationship 380,38 1 csf GABA levels and psychotropics 613-19 dimensions, factor analysis 435-9 drug effects on cardiovascular system 523-6 factor analysis 433.434.438 fast habituation, significance 386,387 galvanic skin response 383

and event related potential 381 in-patients and despramine 591-9 psychophysiological reactivity 382-6 rating scale 46,55,385,387,388,436

xii Subject Index

Desipramine clinical response 593 pharmacokinetics 597 plasma levels 595,597

and amelioration score 594 and response in depression 591-9

Desmethylchlorimipramine, pharmacokinetics 297, 299

Diazepam and acquisition 85 AMP, cyclic induced 95 in anxiety 397 dorsal root ganglion membrane potential 33 GABA-evoked depolarization 3 l-5 and GABA response decay 34 memory effects 81-8, 193-7 and personality trait 289,290 and recall 85-7

5,7-Dihydroxytryptamine and body weight 123-6 and forebrain monoamines I25

Diphenylhydantoin and dementia 562 Dopamine

activity and behaviour 357 activity and feeding 360 antagonism in anorexia 334 blockade and behaviour 356,357 brain and apomorphine treatment I65 -depleting lesions 357, 359 and feeding behaviour 351-60 neostriatal release and anorectic drugs 346 uptake in psychoses and imipramine 215-17

Dopaminergic system, model in attention 585-9 Doxepin

and brain amines 255 and brain 5-HT 256 and 5-HT metabolism and uptake 253-8

Drugs see also antidepressants, classification and psychotic

anorectic 319,320,327-37,342,364-6.371-3 antianxiety and personality 285-9 I, 419-21 antihypoxiotoxic and EEG quantification 469-86 antineoplastic and dementia 562,563 anxiolytic and dementia 562 and cardiovascular system 523-6.527-34.537-43 -induced dementia 561-5 monoaminergic in anorexia 327-9 neuroleptic 459

thyroid function 199-204 nootropic 420,421,445

EEG quantification 469-86 psychoactive, EEG classification 495-500 psycholeptic and emotion with noise 399 psychopharmacology of anorectic 371-3 tranquillizers effects and measurement 39 l-402

Eco-pharmacogenetic model components 314 dependence 313-15

Electrocardiogram (ECG), antidepressant effects 525 Electroencephalogram (EEG)

cinnarazine effects 473,474 classification criteria 497 classification of psychoactive drugs 495-500 and drug classification 463,464 endorphin and enkephalin classification 507-17 etirazepam effects 476-82 evoked responses and naloxone 5.6 hydergine effects 470,471 instenon effects 472,473 isoxsuprine effects 474,475 nicergoline effects 47 I, 472 piracetam effects 475 quantitative and drug properties 469-86

Emotional changes methods for inducing 399 psycholeptic drug effects 402

g-Endorphin amino acid composition I I6 classification 507-17 ligand activity I I9 sequence I I8

Enkephalin classification 507-17 sequence 507-I 7

met-Enkephalin (FK 33-824) behavioural changes 514.515 EEG effects 509 in schizophrenia 511 spectral analysis 5 IO structural formula 509

Entropy and ethanol, Byte processing 261-6 Ethanol

-amphetamine interaction in rodents 13-17 Byte processing 261-6 concentration and cell S’nucleotidase response 24,

25 S’nucleotidase stimulation in cell culture 19-29 spike train analysis and penicillamine 137-43

Etirazetam EEG quantitative effects 476-82 psychometric changes 483

Evoked unit activity 4.5

Fear assessment 77 conditioned and chlordiazepoxide 153-8

Feeding d-amphetamine and 352-5 behavioural analysis 3 19-26 dopaminergicactivity 351-60 drug manipulation 321-6 drugs inhibiting 354 phenothiazenes 323,325

Fenfluramine action in anorexia 367 in anorexia 327 compounds resembling 336,337

Subject Index XIII

and 5-HT uptake 345 synaptosome binding in anorexia 345.346

FK 33-824 see met-enkephalin Fluotracen (SKF 28175)

amitriptyline comparison 51-5 side-effects 56 structure 52

GABA see y-aminobutyric acid Galvanic skin responses

in depression 38 I, 383 normal 384

General Practitioner ResearchGroup,ratingscale 543 Gerbrand operant chamber 154

Haloperidol antiserum specificity 176 dose and serum levels 177, 178 drug interactions 173 radioimmunoassay 174, 175 serum levelsandextrapyramidalsymptoms 180.181 serum level significance 171-83

Hamilton Rating Scale depression 46.55, 387. 388.610 plasma levels in depression 593,594 somatic items 543

Heart assessment 530 psychotropic drug effects 527-34

5-HT see 5-hydroxytryptamine Huntington’s chorea

5-HT uptake and release 277-82 platelet function 279-81

6-Hydroxydopamine 334,335 and feeding 358

5-Hydroxyindoleacetic acid (HIAA) brain and anorectic drugs 344 brain and doxepin 255 and probenecid blockade 256

5-Hydroxytryptamine (5-HT. serotonin) antagonists in anorexia 328,329 brain and apomorphine treatment 166 brain concentration and anorectic drugs 344 brain and doxepin 255 and brain monoamine oxidase activity 63 brain receptor stimulation and anorexia 363-8 p-chlorophenylalanine inhibition 331,332 depletion and body weight 123-6 neurotoxins and raphe lesions 330.33 I turnover and doxepin 256 turnover in Huntington’s chorea 277-82 uptake and antidepressants 465 uptake blockade in phobic anxiety 75-8 uptake inhibition in anorexia 329,330

5-Hydroxytryptaminergic system, drugsaffecting 328 Hyperactivity in children

d-amphetamine tolerance 601-6 continuous performance test 621

Hypermotility, ethanol and amphetamine 16 Hyperthermia

d-amphetamine 15 ethanol I5

Hypothalamus lesions and amphetamine 360 Hypothyroidism, piracetam reaction 207-9

Imipramine effect in psychoses 215-17 structure 52

Information theory 263-5

Lithium effects on cholinesterase 107-9 and exploratory behaviour 37-40 and platelet monoamine oxidase 188

Lorazepam pharmacodynamics; assessment 423-5

Maze and attention 586 drug effects in mice 588

Melitracen structure 52 Memory

and diazepam 81-8, 193-7 experimental assessments 84 noradrenergic 156, I57 tests 82, 83

Meprobamate in anxiety 397 me%-chlorophenyl piperazine causing anorexia 364,

365 Metals and dementia 563 3-Methoxy-4-hydroxyphenylglycol, AHRI 118 effects

45 Methyl phenidate

behavioural and neurochemical effects 129-34 and neurotransmitters 133 and spontaneous motor activity 132 and stereotypy 132

Mianserin cardiovascular effects 523-6 heart effects 527-34

MK 212 and 5-HT uptake 345 Model ofalcoholism 313-15 Monoamine oxidase

activity assay 59.60 brain 61 in brain regions 61.63 and lithium treatment 188 mental disorders 57-66 platelet 59 in platelets in mental disorder 185-90 and substrate 63

Mood, psychopathological reactivity 379-89 Morphine

opiate immobility 310 response in substantia nigra stimulation 1-l 1

xiv Subject Index

Motor activity, L-dopa induced and enzyme inhibition 101-4

Motor incoordination 235 and phencyclidine 236

Multicentre trials and psychiatry 545-57 analysis and interpretation 556, 557 data 555,556 execution 555 experimental design 552-5 methods 548 sample considerations 549-5 I settings 551,552

Muscimol and membrane potential 32 Muscle, skeletal; properties and calcium antagonism

145-51 A, myelin basic protein, amino acid composition I I6

Naloxone response and substantia nigra stimulation I-11

Neostriatum lesions and spiroperidol 269-75 Neurosis, phenelzine response prediction 303-7 Neuroticism and behaviour tests 289 Neurotransmitter

agonists and antagonists and oxtremorine symptoms 243

synaptosome uptake and anorectic drugs 345 Nomifensine dose and depression rating 610 Noradrenaline

and apomorphine treatment I65 uptake and antidepressants 465

Norepinephrine antagonism in anorexia 333,334 metabolism and pyrrolidine derivative 43-8

Norzimelidine 78 5’ Nucleotidase

activity and cell density 23 ECTO characteristics 21 and ethanol concentration 24.25 ethanol stimulation in culture 19-29 production and ethanol withdrawal 26

Pharmacodynamics analysis of phychoactive classification 498 psychotropic drugs and psychometry 417-34

Pharmacokinetics. desipramine 597 Phencyclidine

and body weight 236 motor incoordination 235-8 tolerance development 233-9

Phenelzine effect assessment 305,306 prediction of response in neurosis 303-7

Phenethylamines in anorexia 341-8 Phenobarbitone

plasma levels 249 and sodium valproate interaction 247-5 I urinary excretion 250

Phentermine, blood level significance 427 Phenylethanolamine-Nmethyltransferase inhibition

and motor activity 101-4 fi-Phenylethylamineandbrainmonoamineoxidase 63 Phobic anxiety, serotonin uptake blockade 75-8

Opioid peptides generation, summary I I3 receptors 114, I15

Oxazepam in anxiety 397 blood level significance 428,429

Oxotremorine behaviour effect screening 241-5 and cyproheptadine 244 hypothermia 244

Paediatric pharmacology, drug classification 5 I9 Penicillamine, spike train analysis 137-42 Personality trait and antianxiety drugs 285-9 I Pharmacodependence model 3 13-l 5

Piracetam, hypothyroid child reaction 207-9 Plasma levels and clinical response to drugs in depression

591-9 Platelet

dopamine uptake in psychoses 215-17 function in Huntington’s chorea 279 5-HT uptake and doxepin 257 monoamine oxidase activity in psychoses 64 monoamine oxidase activity in schizophrenia 64 monoamine oxidases in mental disorder 185-90

Platelet aggregation in Huntington’s chorea 277-82 Predation

and p-chlorophenylalanine 224 muricidal model 220 neurochemical lesions 222 serotoninergic mechanisms 219-28

Probenecid blockade of 5-HIAA 256 Procyclidine and feeding behaviour 325 Propranolol

d-, in schizophrenia 633-7 open trial results 637 in tardive dyskinesia 627-31

Psychiatry, multicentre trials 547-57 Psychometrics

aspects of concern 377 definition 375 psychotropicdrug pharmacodynamics 417-34

Tsychometric tests blood level significance 426-9 dose and time effects 422-6

Psychometric variables antidepressant effects 419-21 anxiolytic effects 419-21 nootropic effects 420.421

Psychomotor performance and antianxiety drugs 285-9 I

Psychoses, dopamineuptakeand imipramine 215-17 Psychotropic drugs

and AMP, cyclic 94

TTTTTTTh

classification 443,447-52,456.457. 519 computer classification 465-7 csf GABA levels 613-19 and EEG classification 463,464 heart effects 527-34 nootropes 445 pharmaco-clinical classification in France 455-67 pharmacodynamics 417-34 subdivisions 458,459

Quipazine causing anorexia 364,365

Radioimmunoassay, haloperidol 174, I75 Rats, emotional status and behaviour 163-8 Receptor for opioid peptides 114, I I5 Receptors, 5-HT stimulation and anorexia 363-8 R5-5 I324

antidepressant activity 569-82 assessment methods 570-2 blood pressure effects 576 formula 580 heart output 578 left ventricular contractility 577 monoamine oxidase inhibition 575 pharmacology 569-84 reserpine induced hypothermia 573 reserpine induced ptosis 574 structure 58 I

Schizophrenia alcoholic 64 AMP, cyclic in 69-73 EEG changes and enkephalin 5 I I GABA in csfand psychotropics 613-19 monoamine oxidase 57-66 platelet monoamine oxidase activity 64 d-propranolol 633-7 thyroxine levels and neuroleptics 201 TSH serum levels 202

SCL Anxiety cluster 412 Serotonin see 5-hydroxytryptamine Serotoninergic mechanisms see o/so

5-hydroxytryptamine metabolism and doxepin 253-8 punishment system 156

SKF 28.175 see fluotracen SK 64139 and I-DOPA activation 103 Sodium valproate

phenobarbitone interaction 247-5 I

plasma levels 249.250 urinary excretion 25 I

Spike trains analysis, ethanol and penicillamine effects 137-42 analysis method 139, 263 internal patterns and ethanol 141

Spiroperidol and food intake 354,358 and open field behaviour 272 neostriatal lesions 269-75

Stress induced facilitation of opiate catalepsy 309-I 1 noise and psycholeptic drugs 399

Substantia nigra stimulation and morphine/naloxone responsiveness

l-l I stimulation procedure 2

Suicide degrees and monoamine oxidase activity 188 methods I89 platelet monoamine oxidase 185-90

Tardive dyskinesia S-adrenergic mechanisms 627-31 case history 628. 629

Theophylline and plasma AMP 95 Thyroid function and neuroleptics 199-204 Thyroxine serum levels in schizophrenia and

neuroleptics 201 Tolerance

analysis 605 phencyclidine 233-9 studies 234

Toxicity, aggregated mice 15 Triiodothyronine serum levels in schizophrenia and

neuroleptics 201 Tryptamine and brain monoamineoxidaseactivity 63 Tryptophan, brain and doxepin 225 TSH serum levels in schizophrenia and neuroleptics

202

Weight and phencyclidine 236 and serotonin depletion 123-6

Zimelidine cardiovascular effects 523-6 serotonin uptake in phobic anxiety 75-8